The danger of in-kind drug donations to the Global Fund

The Lancet

Volumn 373, Issue 9670, 2009, Pages 1218-1221

  Baker, Brook K ^a   Ombaka, Eva ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b Ecumenical Pharmaceutical Network   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DEVELOPING COUNTRY; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; FUNDING; GOVERNMENT; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; MALARIA; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 63649111554     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61487-7     Document Type: Note

References (48)

1. The Global Fund to Fight AIDS. Tuberculosis and Malaria. Summary of Global Fund Board discussions and decisions related to product/service donation. 2007.
2. World Health Organization. Guidelines for Drug Donations. Revised 1999. http://whqlibdoc.who.int/hq/1999/WHO_EDM_PAR_99.4.pdf (accessed Jan 25, 2008).
3. World Health Organization. First-year experiences with the Interagency Guidelines for Drug Donations (2000). http://whqlibdoc.who.int/hq/2000/WHO_EDM_PAR_2000.1.pdf (accessed Jan 25, 2008).
4. Caines K., and Lush L. Impact of public-private partnerships addressing access to pharmaceuticals in selected low and middle income countries: a synthesis report from studies in Botswana, Sri Lanka, Uganda and Zambia. Initiative on Public-Private Partnerships for Health (2004). http://www.dfid.gov.uk/Pubs/files/ipph-accesspharmaceuticals-synthesis.p df (accessed Jan 25, 2008).
5. Caines K. Global health partnerships and neglected diseases, DfID Health Resource Centers (2004). http://www2.ohchr.org/english/issues/development/docs/WHO_4.pdf (accessed Jan 25, 2008).
6. Shretta R., Walt G., Brugha R., and Snow R.W. A political analysis of corporate drug donations: the example of Malarone® in Kenya. Health Policy Plan 16 (2001) 161-170
7. Hechmann R., and Bunde-Birouste A. Drug donations in emergencies, the Sri Lankan post-tsunami experience. J Humanitarian Asst (2007). http://jha.ac/2007/09/26/drug-donations-in-emergencies-the-sri-lankan-po st-tsunami-experience (accessed Jan 25, 2008).
8. Autier P., Govindarah R., Gray R., Lakshminarayanan R., Nassery H.G., and Schmets G. Drug donations in post-emergency situations. World Bank 2002. http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/Resource s/281627-1095698140167/Nassery-DrugDonation-whole.pdf (accessed Jan 25, 2008).
9. Guilloux A, Moon S. Hidden price tags: disease-specific drug donations: costs and alternatives. 2001.
10. World Health Organization. Global strategy for containment of antimicrobial resistance (2001). http://www.who.int/csr/resources/publications/drugresist/en/EGlobal_Stra t.pdf (accessed Jan 25, 2008).
11. Oyediran A., Ddumba E., Ochola S., Lucas A.O., Koporc K., and Dowdle W.R. A public-private partnership for malaria control: lessons from the Malarone Donation Programme. Bull World Health Organ 80 (2002) 817-821
12. Congressional Budget Office. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. Congress of the United States, July, 1998. http://www.cbo.gov/ftpdocs/6xx/doc655/pharm.pdf (accessed Jan 29, 2008).
13. Reiffen D., and Ward M.R. Generic drug industry dynamics. Rev Econ Stat 87 (2005) 37-49
14. Bae J. Research on pharmaceutical drug development, use, and outcomes: drug patent expirations and the speed of generic entry. Health Services Res 32 (1997) 87-101
15. Dalen D.M., Strøm S., and Haabeth T. Price regulation and generic competition in the pharmaceutical market. University of Oslo Health Econ Res Prog 2006. http://www.hero.uio.no/publicat/2006/HERO2006_1.pdf (accessed Jan 29, 2008).
16. Morton F. Entry decisions in the generic pharmaceutical industry. RAND J Econ 30 (1999) 421-440
17. Hass J., Phillips K.A., Gerstenberger E., and Seger A. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med 142 (2005) 891-897
18. Saha A., Grabowski H., Birnbaum H., Greenberg P., and Bizan O. Generic competition in the US pharmaceutical industry. Int J Econ Bus 13 (2006) 15-38
19. Reiffen D., and Ward M. Branded generics as a strategy to limit cannibalization of pharmaceutical markets (2005). http://www.uta.edu/faculty/mikeward/brandedgenerics.pdf (accessed Jan 29, 2008).
20. Frank R.G. The ongoing regulation of generic drugs. N Engl J Med 357 (2007) 1993-1996
21. Henry D., and Lexchin J. The pharmaceutical industry as a medicines provider. Lancet 360 (2002) 1590-1594
22. Moreno-Torres I., Puig-Junoy J., and Borrell-Arqué J.-R. Generic entry into a regulated pharmaceutical market (2007). http://ssrn.colm/abstract=992685 (accessed Jan 25, 2008).
23. Frank R.G., and Salkever D.S. Generic entry and pricing of pharmaceuticals. J Econ Manage Strategy 6 (1997) 75-90
24. Hudson J. Generic take-up in the pharmaceutical market following patent expiry: a multi-country study. Int Rev Law Econ 24 (2000) 103-112
25. Rudholm N. Entry and the number of firms in the Swedish pharmaceutical market. Rev Ind Organ 19 (2001) 351-364
26. Lewis-Lettington R., and Munyi P. Willingness and ability to use TRIPS flexibilities: Kenya Case Study. DfID, Sept 2004. http://www.dfid.gov.uk/pubs/files/dfidkenyareport.pdf (accessed Jan 25, 2008).
27. World Community Advisory Board. Meeting with Indian generic drugs industry (Jan 6-7, 2005). http://www.i-base.info/wcab/PDF/W-CAB-Mumbai-report-jul05.pdf (accessed Jan 25, 2008).
28. Chien C. HIV/AIDS drugs for sub-Saharan Africa: how do brand and generic supply compare?. PLoS One (March 2007). http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1805689&blobty pe=pdf (accessed Jan 29, 2008).
29. Médecins Sans Frontières. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. Revised Sept 2007. http://www.accessmed-msf.org/fileadmin/user_upload/diseases/hiv-aids/UTW 10_RSep_horizontal.pdf (accessed Jan 29, 2008).
30. World Health Organization. A summary report from the global price reporting mechanism on antiretroviral drugs (July 2007). http://www.who.int/hiv/amds/GPRMsummaryJuly2007.pdf (accessed Jan 29, 2008).
31. Pérez-Casas C., Herranz E., and Ford N. Pricing of drugs and donations: options for sustainable equity pricing. Trop Med Int Health 6 (2001) 960-964
32. Competition Bureau Canada. Canadian generic drug sector study (Oct 2007). http://www.competitionbureau.gc.ca/epic/site/cb-bc.nsf/vwapj/Competition %20Bureau%20Generic%20Drug%20Sector%20Study.pdf/$FILE/Competition %20Bureau%20Generic%20Drug%20Sector%20Study.pdf (accessed Feb 1, 2008).
33. Baker B. Processes and issues for improving access to medicines: willingness and ability to use TRIPS-compliant flexibilities in developing countries. DfID Aug 2004. http://www.dfid.gov.uk/pubs/files/dfidbrookbakertrips.pdf (accessed Feb 1, 2008).
34. Thorpe P. Study on the implementation of the TRIPS Agreement in developing countries (2001). http://www.iprcommission.org/papers/pdfs/study_papers/sp7_thorpe_study.p df (accessed Dec 14, 2007).
35. Musungu S., and Oh C. The use of flexibilities in TRIPS by developing countries: can they promote access to medicines? (2006). http://www.southcentre.org/publications/SouthPerspectiveSeries/TheUseOfF lexibilitiesInTripsFinal.pdf (accessed Dec 14, 2007).
36. World Health Organization. Measuring transparency in medicines registration, selection and procurement: four country assessment studies (2006). http://www.who.int/medicines/areas/policy/goodgovernance/Transparency4Co untryStudy.pdf (accessed Dec 14, 2007).
37. Ratanawifitrasin S., and Wondemagegnehu E. Effective drug registration: a multi-country study (2002). http://whqlibdoc.who.int/hq/2002/9241562064.pdf (accessed Dec 14, 2007).
38. European Community. Better regulation of pharmaceuticals: towards a simpler, clearer and more flexible framework on variations (Oct 20, 2006). http://ec.europa.eu/enterprise/pharmaceuticals/varreg/variations_consult ation_paper_codecision_20070710.pdf (accessed Dec 14, 2007).
39. Correa C. Protection of data submitted for the registration of pharmaceuticals: implementing the standards of the TRIPS Agreement. 2002.
40. Kimani D. Drug companies fight over Kenyan market. Nationmedia.com Jan 23, 2006. http://www.nationmedia.com/eastafrican/23012006/News/news230120067.htm (accessed Feb 4, 2008).
41. Thompson M.B. Proceedings: HIV/AIDS donations and price reductions in sub-Saharan Africa. Global Alliance for Women's Health (April 15, 2003). http://www.gawh.org/programmes/04_15_03/pdf/proceedings.pdf?CAMEFROM=SYM POSIA&id=13 (accessed Jan 25, 2008).
42. World Health Organization. Prioritizing second-line antiretroviral drugs for adults and adolescents: a public health approach 2007. http://www.who.int/hiv/pub/meetingreports/second_line_art_report_2008.pd f (accessed Feb 4, 2008).
43. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: a public health approach 2007. http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf (accessed Feb 4, 2008).
44. Uganda: Factory to boost ARV rollout, Plus News (Oct 10, 2007). http://www.plusnews.org/Report.aspx?ReportId=74715 (accessed Feb 4, 2008).
45. Mangwiro C. Brazil offers drug factory to AIDS ravished Mozambique. Reuters AlertNet (May 29, 2007). http://www.alertnet.org/thenews/newsdesk/L29579337.htm (accessed Feb 4, 2008).
46. Kahn T. Ranbaxy, CIH in sub-Saharan antiretroviral joint venture. Bus Day (Johannesburg) (Feb 7, 2006). http://www.businessday.co.za/articles/article.aspx?ID=BD4A150867 (accessed Feb 4, 2008).
47. Kahn T. Adcock Ingram mounts AIDS challenge. Bus Day (Johannesburg) (Feb 7, 2006). http://www.businessday.co.za/articles/economy.aspx?ID=BD4A396084 (accessed Feb 4, 2008).
48. Kimani D. Drug companies fight over Kenyan market. Nationmedia.com Jan 23, 2006. http://www.nationmedia.com/eastafrican/23012006/News/news230120067.htm (accessed Feb 4, 2008).